• Potential conflict of interest: Stuart Gordon has received research/grant support from Abbott Laboratories, AbbVie, Bristol-Myers Squibb, Exalenz Bioscience, Gilead Sciences, GlaxoSmithKline, Intercept Pharmaceuticals, Merck, Roche, and Vertex Pharmaceuticals; been a consultant for Achillon Pharmaceuticals, Bristol-Myers Squibb, CVS Caremark, Gilead Sciences, Merck, Novartis, and Vertex; and has served on data monitoring boards for Janssen Pharmaceuticals. Leland J. Yee and Eduardo Bruno Martins are employees of Gilead Sciences and own stock in the company.

No abstract is available for this article.